Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16479283 | 1.00 | FURIN (0.44) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL25124339 | 0.91 | FURIN (0.43) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL22147928 | 0.91 | FURIN (0.41) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL25765345 | 0.91 | SIRT2 (0.42) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL21901403 | 0.90 | SIRT2 (0.42) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL25098213 | 0.90 | SIRT2 (0.42) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL20750038 | 0.90 | SIRT2 (0.42) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL21318749 | 0.90 | SIRT2 (0.42) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL16202562 | 0.90 | SIRT2 (0.42) | FURINHTTSMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL24638624 | 0.90 | SIRT2 (0.42) | FURINHTTSMN1; SMN2SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878047-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | FURIN 1732/4885HTT 4197/4885SMN1; SMN2 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.